CASI Pharmaceuticals, Inc., a biopharmaceutical company specializing in developing novel therapies, recently appointed Rong Chen as the company’s new chief medical officer.
Chen has more than 20 years of experience in pharmaceutical regulatory affairs and clinical development.
"Dr. Chen brings a strong and successful track record in new drug development and pipeline enrichment in a variety of different therapeutic areas particularly in oncology," CASI CEO Ken Ren said. "He will lead our clinical and regulatory activities in both North America and greater China and will contribute to the expansion of our product pipeline through our dual development strategy of acquisition and internal development."
Chen has been the global medical expert and medical director of Bayer-Schering Pharma Asia Pacific Area and previously worked as medical director at Sanofi China. He previously worked as the chief medical governance officer and area medical director for GSK China/Hong Kong Area. In 2010, he became vice president with responsibility for the company’s overall drug and vaccine product registration.
“I am very excited to be part of the company's team to advance the research and clinical development of its growing pipeline of drugs for cancer and other unmet medical needs,” Chen said. “I look forward to leading the effort to successfully develop them and to bring them to patients. This is a very exciting time to join the CASI family and I look forward to working with the team to achieve the many milestones to come."
Chen earned his medical degree at Shandong Medical University and his Ph.D. in clinical pharmacology from the Royal Adelaide Hospital at the University of Adelaide in Australia. He has published various articles as a co-author, and has given several international conference presentations.